Anh-Thu Lam, Ph.D., is a technical specialist in Sterne Kessler's Biotechnology & Chemical Practice Group, where she is involved in the preparation and prosecution of U.S. and foreign patent applications. Her background and technical areas of expertise include human genetics, molecular and cell biology, neuroscience and biochemistry.
Prior to joining the firm, Anh-Thu worked as a clinical data scientist in support of the FDA Center for Drug Evaluation and Research, where she developed and executed safety data review plans for INDs and NDAs submitted to the Office of New Drugs. She also conducted comprehensive and in-depth clinical safety analyses to maximize clinical insight for the clinical review teams. Anh-Thu received her Ph.D. in Human Genetics and Molecular Biology from The Johns Hopkins University School of Medicine. Her doctoral work was predicated on evaluating how noncoding variation in DNA regulatory sequences contribute to phenotype variation and disease risk/presentation in the context of cystic fibrosis. Anh-Thu also completed a postdoctoral training in the Department of Genetic Medicine at Johns Hopkins. Her studies revolved around determining the effects of schizophrenia-associated variants in iPSCs using CRISPR technologies.
Before starting her graduate work, Anh-Thu received a B.S. in Biochemistry and a B.A. in Spanish from the University of Vermont. While there, she completed an honors thesis focused on investigating tyrosine 504 phosphorylation on the regulation of Collapsin Response Mediator Protein 1, a key effector protein involved in neuronal guidance and brain development. After completing her undergraduate studies, Anh-Thu worked at Boston Children's Hospital/Harvard Medical School researching an array of developmental disorders of the human brain. Along with a team of physician scientists, she investigated the prevalence of somatic mutations in several neurodevelopmental diseases associated with autism and intellectual disability.
Anh-Thu has authored or co-authored 15 scientific articles published in peer-reviewed journals.
Selected Technical Publications
- “CRISPR Del/Rei: A simple, flexible and efficient pipeline for scarless genome editing.” Wahbeh, M.*, Feuer, K.*, Abdollahi, S., Yovo, C., Rabie, E., Lam, A., Young, L., Avramopoulos, D. Submitted to Nature Methods. 2, Mar. 2022.
- “Transcriptomic data of chlozapine-treated Ngn2-induced human excitatory neurons.” Lam, A.*, Peng, X.*, Das, D.*, Bader, J., Avramopoulos, D. Accepted at Data in Brief. 19, Feb. 2021. PMID: 33681435
- “Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis.” A.N. Lam, M. Atalar, B. Vecchio-Pagan, C. A. Shelton, D.L. Osorio, et al. (2019) JCI. PMID: 31581148
- “Integrated genome and transcriptome sequencing identifies a noncoding mutation in the genome replication factor DONSON as the cause of microcephaly-micromelia syndrome.” G. D. Evrony, D. R. Cordero, J. Shen, J. N. Partlow, T. W. Yu, R. E. Rodin, R. S. Hill, M. E. Coulter, A. N. Lam, et al. (2017). Genome Res 27(8): 1323-1335. PMID: 28630177
- “Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates Multiple Genetic Mechanisms.” A. M. D'Gama, S. Pochareddy, M. Li, S. S. Jamuar, R. E. Reiff, A. N. Lam, N. Sestan, and C. A. Walsh. (2015). Neuron 88: 910-917.PMID: 26637798
- “Somatic mutations in cerebral cortical malformations.” Jamuar, S. S., A. N. Lam, M. Kircher, A. M. D'Gama, J. Wang, et al. (2014). NEJM 371: 733-743. PMID: 25140959